Eyeing big returns, drugmakers ready new hepatitis-C drug launches

More patients are seeking treatments with even fewer side effects and shorter durations.

Five things for pharma marketers to know: Wednesday, July 29

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo ...

Pfizer ends bid for OTC Lipitor

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Point of Care: Point of Where?

With rare exceptions, the point of care used to be one of three places: the doctor's office, the hospital or the pharmacy. But with advancing ...

Leadership Exchange: 21st Century Promotion

From the 21st Century Cures Act to Amarin's off-label suit, Marc Iskowitz asks seven experts what the confluence of policy developments means for pharma promotion.

Welcome to MM&M's 2015 Agency Issue!
Here you'll find original profiles, findings of our annual business barometer, all 100 North American healthcare marketing and advertising firms ranked by 2014 revenue, an infographic of the agency universe, a Q&A with holding-company level health execs, and the Agency A to Z definitive annual directory.

Latest

Turing names J&J vet for chief comms role

Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.

Graphic: the new hepatitis-C drug market

Graphic: the new hepatitis-C drug market

View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

MMC hires first CMO

The integrated agency's pharmaceutical business now brings in half its billings.

Five things for pharma marketers to know: Monday, July 27

Five things for pharma marketers to know: Monday, July 27

Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend

FDA approves first PCSK9 inhibitor

FDA approves first PCSK9 inhibitor

The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.

The MM&M Weekly News Quiz: July 24

The MM&M Weekly News Quiz: July 24

Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

BMS US sales are down, despite growing Opdivo adoption

BMS US sales are down, despite growing Opdivo adoption

Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.

Physicians Interactive acquires Quantia

Physicians Interactive acquires Quantia

The deal is expected to complement the company's digital health platform.

Five things for pharma marketers to know: Thursday, July 23

Five things for pharma marketers to know: Thursday, July 23

Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.

Praluent's FDA review looms, but questions persist

Praluent's FDA review looms, but questions persist

A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Agency Spotlight


Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.